Headache News and Research

Latest Headache News and Research

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.

20 Feb 2014

Stress does lead to more headaches, new study reveals

A new study provides evidence for what many people who experience headache have long suspected—having more stress in your life leads to more headaches. The study released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

20 Feb 2014

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.

20 Feb 2014

Ticks infected with the bacterium that causes Lyme disease widespread in San Francisco Bay Area

As winter turns to spring and many Northern Californians plan outdoor adventures, a mysterious, potentially debilitating threat looms.

19 Feb 2014

New research may provide insight on how dengue virus gains entry into cells

Dengue fever, an infectious tropical disease caused by a mosquito-borne virus, afflicts millions of people each year, causing fever, headache, muscle and joint pains and a characteristic skin rash. In some people the disease progresses to a severe, often fatal, form known as dengue hemorrhagic fever.

18 Feb 2014

Scientists measure how well football helmet designs protected against traumatic brain injury

A new study finds that football helmets currently used on the field may do little to protect against hits to the side of the head, or rotational force, an often dangerous source of brain injury and encephalopathy.

18 Feb 2014

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

Valproic acid is one of the most widely prescribed drugs for the treatment of epilepsy. It has also been shown to be effective for the treatment of mood disorders and migraine headaches.

17 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby - twice as long as previously recognized, according to a large study presented at the American Stroke Association's International Stroke Conference 2014.

14 Feb 2014

Parents and doctors must be aware and prepared to treat strokes in children

Parents and healthcare professionals must be aware that children can have strokes and be prepared to respond to symptoms, according to research presented at the American Stroke Association's International Stroke Conference 2014.

13 Feb 2014

Stroke hospitalization and death rates associated with weather changes

Stroke hospitalization and death rates may rise and fall with changes in environmental temperature and dew point, according to research presented at the American Stroke Association's International Stroke Conference 2014.

12 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.

11 Feb 2014

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

Loyola University neuropsychologist find little evidence that chronic traumatic encephalopathy actually exists

The media have widely reported that a debilitating neurological condition called chronic traumatic encephalopathy is a well-established disease in retired athletes who played football and other contact sports.

28 Jan 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection.

From Novo Nordisk 21 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

21 Jan 2014

Headache News and Research

Latest Headache News and Research

XenoPort reports net loss of $19.1 million for fourth quarter 2013

Stress does lead to more headaches, new study reveals

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Ticks infected with the bacterium that causes Lyme disease widespread in San Francisco Bay Area

New research may provide insight on how dengue virus gains entry into cells

Scientists measure how well football helmet designs protected against traumatic brain injury

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Parents and doctors must be aware and prepared to treat strokes in children

Stroke hospitalization and death rates associated with weather changes

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Loyola University neuropsychologist find little evidence that chronic traumatic encephalopathy actually exists

S. pneumoniae predicts acute sinusitis microbial response

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in